How body composition and psychosocial health relate to outcomes for people receiving immune checkpoint inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project will use pre-treatment CT scans at the L3 level to measure body composition and collect questionnaires on psychosocial factors and drug-related problems in adults starting immune checkpoint inhibitors. Clinical outcomes such as treatment toxicity, tumor response, and patient-reported quality of life will be followed through medical records and patient reports. No experimental treatment is given; researchers will analyze associations between body composition, psychosocial and medication issues, and clinical progression. Enrollment and follow-up visits take place at Hacettepe University Faculty of Pharmacy in Ankara.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 years or older
* Having undergone a CT scan (at the L3 level) prior to treatment
* No severe mental disorder and able to communicate effectively
* Provided written informed consent

Exclusion Criteria:

* Did not provide written informed consent
* Patients deemed unsuitable by the physician

Where it's running

• Hacettepe University Faculty of Pharmacy, Department of Clinical Pharmacy
  Ankara, Altındağ, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: İzgi BAYRAKTAR, PhD (c)- Lecturer
• Email: izgibayraktar@gmail.com
• Phone: +905342996472

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DS010 in advanced cancer with cachexia: safety and early signals in adults

  This study tests DS010 in adults with cancer and cachexia to see if it is safe and whether it might help with their condition.

  Recruiting at 4 sites Phase 1/2 Dartsbio Pharmaceuticals Ltd. · Concord West, New South Wales and 3 other locations · NCT07921576

• Spatial multi-omics and AI-based early warning for pancreatic cancer cachexia

  This study tests whether spatial multi-omics data can reveal how the tumor and body metabolism interact in pancreatic cancer cachexia and whether a multimodal AI model can predict cachexia early in adults with pancreatic ductal adenocarcinoma.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07670286

• Pathogenesis and Reversal Strategies for Cancer Cachexia Using Multi-Omics

  This study uses multiple omics methods and nutritional interventions to try to find causes and reversal strategies for cachexia in adults with gastrointestinal cancers.

  Recruiting China Medical University, China · Shenyang, Liaoning · NCT07519837

• GB18 injection for tumor cachexia in cancer patients

  This study tests GB18, a humanized GDF15 antibody, to see if it helps cancer patients with cachexia when given as subcutaneous injections.

  Recruiting at 2 sites Phase 1 Kexing Biopharm Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07519564

• Nanocrystalline megestrol acetate with chemoradiation for locally advanced cervical cancer

  This Phase 1 trial tests whether taking nanocrystalline megestrol acetate by mouth can prevent or reduce weight and muscle loss in adults with locally advanced cervical cancer who are receiving concurrent chemoradiotherapy.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07338487

• Mindfulness program using loving‑kindness, compassion, joy, and equanimity for healthcare professionals

  This program will test whether a six-week online mindfulness course teaching loving‑kindness, compassion, joy, and equanimity can reduce stress in full‑time physicians.

  Recruiting University of California, Los Angeles · Los Angeles, California · NCT07283744

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.